Global Dermatology Drugs Market Size Forecast to 2021

Posted by Kavita on March 22nd, 2021

Bharat Book Bureau Provides the Trending Market Research Report on “Dermatology Drugs Global Market Report 2021” under Life Sciences Category. The report offers a collection of superior market research, market analysis competitive intelligence and Market reports.

Global Dermatology Drugs Market Report 2021: COVID 19 Impact and Recovery to 2030 from The provides the strategists, marketers and senior management with the critical information they need to assess the global dermatology drugs market as it emerges from the Covid 19 shut down.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.

Request a free sample copy of Dermatology Drugs Market Report @

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.

• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.

• Create regional and country strategies on the basis of local data and analysis.

• Identify growth segments for investment.

• Outperform competitors using forecast data and the drivers and trends shaping the market.

• Understand customers based on the latest market research findings.

• Benchmark performance against key competitors.

• Utilize the relationships between key data sets for superior strategizing.

• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

• Report will be updated with the latest data and delivered to you within 3-5 working days of order.


Where is the largest and fastest growing market for the dermatology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Dermatology Drugs market global report from the answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider dermatology drugs market, and compares it with other markets.

• The market characteristics section of the report defines and explains the market.

• The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the Covid 19 virus and forecasting its recovery.

• Market segmentations break down market into sub markets.

• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of Covid 19 for all regions, key developed countries and major emerging markets.

• Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

• The dermatology drugs market section of the report gives context. It compares the dermatology drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, dermatology drugs indicators comparison.


Markets Covered: 1) By Type: Acne; Dermatitis; Psoriasis; Other Drugs for Dermatology Diseases

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/ Drug Stores; Others

3) By Route Of Administration: Oral; Parenteral; Others

4) By Drug Classification: Branded Drugs; Generic Drugs

5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs

Companies Mentioned: Johnson & Johnson; Allergan Plc; Galderma S.A; Novartis AG; GlaxoSmithKline Plc

Metrics Covered: Number of Enterprises; Number of Employees

Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam


Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, dermatology drugs indicators comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Major companies in the dermatology drugs market include Johnson & Johnson; Allergan Plc; Galderma S.A; Novartis AG and GlaxoSmithKline Plc.

The global dermatology drugs market is expected to grow from .57 billion in 2020 to .49 billion in 2021 at a compound annual growth rate (CAGR) of 7.8%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach .83 billion in 2025 at a CAGR of 12%.

The dermatology drugs market consists of sales of dermatology drugs by entities (organizations, sole traders and partnerships) that produce dermatology drugs to treat skin diseases. This industry includes establishments that produce drugs to treat diseases such as rosacea, dermatitis, hyperhidrosis, androgenic alopecia, acne, microbial infections and other skin disorders. The dermatology market is segmented into acne; dermatitis; psoriasis; and other drugs for dermatology diseases.

Asia Pacific was the largest region in the global dermatology drugs market, accounting for 36% of the market in 2020. North America was the second largest region accounting for 27% of the global dermatology drugs market. Africa was the smallest region in the global dermatology drugs market.

Drug manufacturing companies are using genome testing (genetic diagnosis) to reduce the time and costs spent in clinical trials. A clinical trial is a complex process and it often takes months for a drug to be available in the market. This deprives patients of cost-effective treatment. Researchers in the Rockefeller University used genomic testing and data analytics to predict the response of psoriasis patients for a given treatment. Genomic testing algorithms collect gene-expression data from skin biopsies and detect activity in 50,000 different genes. This technique can predict the response of a patient with an accuracy of 95% and within 12 weeks, thus saving significant time for clinical trials and the launch of new drugs.

High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of dermatology drugs manufacturers.

The dermatology drugs market was mainly driven by rapid growth in emerging markets in the historic period. Emerging markets growth was aided by rising disposable income, stable political environment and increasing foreign investments in these countries. For instance, according to the IMF, China’s GDP grew from trillion in 2015 to .6 trillion in 2018. Additionally, according to the World Economic Outlook Reports by the IMF, emerging markets and developing economies together registered a growth of 4.0% in 2015 and this increased to 4.5% in 2018. Thus, strong economic growth boosted the demand for dermatology drugs and this drove the market during the historic period.

Browse our full report with Table of Content:

About Bharat Book Bureau:

Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 4,80,000 reports and insights that includes latest Market Study, Market Trends & Analysis, Forecasts Customized Intelligence, Newsletters and Online Data bases. Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.

Contact us at:

Bharat Book Bureau

Tel: +91 22 27810772 / 27810773



Like it? Share it!


About the Author

Joined: June 10th, 2019
Articles Posted: 320

More by this author